These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 34754219)

  • 1. Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole.
    Mafuru M; Wu S; Mayala H; Msengwa Z; Phillip A; Mgone C
    Pharmgenomics Pers Med; 2021; 14():1379-1389. PubMed ID: 34754219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.
    Resztak M; Zalewska P; Wachowiak J; Sobkowiak-Sobierajska A; Główka FK
    Eur J Clin Pharmacol; 2024 Nov; 80(11):1829-1840. PubMed ID: 39240338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring and
    Chen X; Xiao Y; Li H; Huang Z; Gao J; Zhang X; Li Y; Van Timothee BM; Feng X
    Transl Pediatr; 2022 Aug; 11(8):1311-1322. PubMed ID: 36072540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
    Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
    Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases.
    Huang Q; Liu Q; Yin T; Hu L; Ding H; Liu S; Jiang Y
    Eur J Clin Pharmacol; 2020 Jun; 76(6):833-842. PubMed ID: 32157329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
    Chuwongwattana S; Jantararoungtong T; Chitasombat MN; Puangpetch A; Prommas S; Dilokpattanamongkol P; Watcharananan SP; Sukasem C
    Drug Metab Pharmacokinet; 2016 Apr; 31(2):117-22. PubMed ID: 26861072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
    Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
    Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.
    Blanco Dorado S; Maroñas Amigo O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Br J Clin Pharmacol; 2020 Aug; 86(8):1661-1666. PubMed ID: 32110830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Influence of Proinflammatory Cytokines on Voriconazole Trough Concentration in Patients With Different Forms of Hematologic Disorders.
    Mafuru M; Wu S; He S; Lu X; Huang J; Jiang H
    J Clin Pharmacol; 2019 Oct; 59(10):1340-1350. PubMed ID: 30997931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
    Fujita Y; Araki T; Okada Y; Aomori T; Shimizu R; Tomizawa T; Hiromura K; Nojima Y; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2013 Feb; 38(1):74-6. PubMed ID: 22971159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.
    García-García I; Dapía I; Montserrat J; Martinez de Soto L; Bueno D; Díaz L; Queiruga J; Rodriguez Mariblanca A; Guerra-García P; Ramirez E; Frías J; Pérez Martínez A; Carcas-Sansuan AJ; Borobia AM
    Front Pharmacol; 2021; 12():717932. PubMed ID: 34744712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients].
    Qu HL; Guo DD; Xu T; Li Z; Yin J; Tian XP; Kong DQ; Zhu XM; Miao LY; Wu DP; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2018 Mar; 39(3):202-206. PubMed ID: 29562464
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.
    Qi F; Zhu L; Li N; Ge T; Xu G; Liao S
    Int J Antimicrob Agents; 2017 Apr; 49(4):403-409. PubMed ID: 28159656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro study of the variable effects of proton pump inhibitors on voriconazole.
    Niece KL; Boyd NK; Akers KS
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5548-54. PubMed ID: 26124167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a mathematical prediction model for voriconazole stable maintenance dose: a prospective study.
    Zhou L; Li M; Li H; Guo Z; Gao Y; Zhang H; Qin F; Sang Z; Xing Q; Cheng L; Cao W
    Front Cell Infect Microbiol; 2023; 13():1157944. PubMed ID: 37565064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.